Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 11/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24981887 | 0.79 | HTT (0.40) | HTTNAMPTTP53TSHRLMNA | |
| SCHEMBL4111848 | 0.72 | HTT (0.40) | HTTNAMPTTP53TSHRLMNA | |
| SCHEMBL3432500 | 0.72 | HTT (0.40) | HTTTP53TSHRLMNAFABP4 | |
| SCHEMBL23089860 | 0.72 | HTT (0.43) | HTTNAMPTTP53TSHRLMNA | |
| SCHEMBL6300741 | 0.72 | HTT (0.58) | HTTTP53TSHRLMNAFABP4 | |
| SCHEMBL1157477 | 0.72 | HTT (0.58) | HTTTP53TSHRLMNAFABP4 | |
| SCHEMBL13284444 | 0.72 | HTT (0.46) | HTTTP53TSHRLMNAFABP4 | |
| SCHEMBL4102300 | 0.71 | HTT (0.42) | HTTTP53TSHRLMNAFABP4 | |
| SCHEMBL3581192 | 0.71 | CA12 (0.52) | HTTTSHRLMNA | |
| SCHEMBL3243207 | 0.70 | POLB (0.46) | HTTTP53TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183380-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HOFFMANN-LA ROCHE, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227570-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2A | HTT 1042/4885NAMPT 2203/4885CYP2C9 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.